Figure 3.

Activin blockade by ACVR2B/Fc preserved muscle and fat in male KPC mice but not in females. (A) Treatment schema and number of doses. Administration of ACVR2B/Fc (2B/Fc) was initiated when mice met early criteria and was administered every 5 days (15 mg/kg body weight i.p.) with vehicle control mice receiving PBS on the same schedule. (B) ACVR2B/Fc prevented wasting with tumour progress in male KPC mice but not the female counterpart. (C) ACVR2B/Fc did not significantly affect survival and tumour weight in either sex. (D) ACVR2B/Fc preserved skeletal muscle and fat mass in males. Sample size: n = 6–11; *P < 0.05, **P < 0.01, ***P < 0.001.